Clinical Focus

  • Diagnostic Radiology

Academic Appointments

  • Clinical Assistant Professor, Radiology

Honors & Awards

  • Certificate of Distinction in Quality and Safety, Graduate Medical Education - Loyola University Medical Center (2016)
  • Cum Laude Award - Educational Exhibit, Radiologic Society of North America (2015)
  • Magis Star Award for Professionalism, Loyola University Medical Center (2014)
  • Graduation with Distinction, University of Kentucky College of Medicine (2013)
  • Summa cum Laude, University of Kentucky (2009)
  • Phi Beta Kappa, University of Kentucky (2009)

Professional Education

  • Board Certification: American Board of Radiology, Diagnostic Radiology (2019)
  • Residency: Loyola University Medical Center Dept of Radiology (2018) IL
  • Fellowship: Stanford University Radiology Fellowships (2019) CA
  • Internship: Loyola University Internal Medicine Residency (2014) IL
  • Medical Education: University of Kentucky College of Medicine Registrar (2013) KY
  • Fellowship, Stanford University, Body Imaging (2018-2019)
  • Residency, Loyola University Medical Center, Diagnostic Radiology (2018)
  • Internship, Loyola University Medical Center, Internal Medicine (2014)
  • M.D., University of Kentucky College of Medicine (2013)
  • B.S., University of Kentucky College of Arts and Sciences, Biology Major, Spanish Minor, Honors Program (2009)

All Publications

  • Ultrasound Liver Imaging Reporting and Data System (US LI-RADS) Visualization Score: a reliability analysis on inter-reader agreement. Abdominal radiology (New York) Tiyarattanachai, T., Bird, K. N., Lo, E. C., Mariano, A. T., Ho, A. A., Ferguson, C. W., Chima, R. S., Desser, T. S., Morimoto, L. N., Kamaya, A. 2021


    BACKGROUND & AIM: The American College of Radiology Ultrasound Liver Imaging Reporting and Data System (ACR US LI-RADS) Visualization Score conveys the expected level of sensitivity of screening and surveillance ultrasound exams in patients at risk for hepatocellular carcinoma (HCC). We sought to determine inter-reader agreement of the Visualization Score which is currently unknown.METHODS: Consecutive 6998 ultrasound HCC screening and surveillance studies in 3115 patients from 2017 to 2020 were retrospectively retrieved. Of these, 6154 (87.9%) studies were Visualization A (No or minimal limitations), 709 (10.1%) were Visualization B (Moderate limitations), and 135 (1.9%) were Visualization C (Severe limitations). Randomly sampled 90 studies, with 30 studies in each Visualization category, were included for analysis. Nine radiologists (3 senior attendings, 3 junior attendings and 3 body imaging fellows) blinded to the original categorization independently reviewed each study and assigned a Visualization Score. Intraclass correlation coefficient (ICC) was used to quantify inter-reader agreement.RESULTS: ICC among all 9 radiologists was 0.70 (95% CI 0.63-0.77). ICCs among senior attendings, junior attendings and body imaging fellows were 0.68 (CI 0.58-0.76), 0.72 (CI 0.62-0.80) and 0.76 (CI 0.68-0.83), respectively. Subgroup analysis by liver parenchyma was further performed. ICC was highest in the patient group with normal liver parenchyma (0.69, CI 0.56-0.81), followed by steatosis (0.66, CI 0.54-0.79) and cirrhosis (0.58, CI 0.43-0.73), respectively.CONCLUSIONS: US LI-RADS Visualization Score is a reliable tool with good inter-reader agreement that can be used to indicate the expected level of sensitivity of a screening and surveillance ultrasound examination for detecting focal liver observations.

    View details for DOI 10.1007/s00261-021-03067-y

    View details for PubMedID 34228197

  • Cystic artery velocity as a predictor of acute cholecystitis. Abdominal radiology (New York) Perez, M. G., Tse, J. R., Bird, K. N., Liang, T., Brooke Jeffrey, R., Kamaya, A. 2021


    To evaluate angle-corrected peak systolic cystic artery velocity (CAv) as a predictor of acute cholecystitis among patients presenting to the emergency department (ED) with right upper quadrant (RUQ) pain.In this IRB-approved and retrospective study, CAv was evaluated in 73 patients, 43 who underwent definitive treatment with cholecystectomy or percutaneous cholecystostomy and 30 control patients without clinical suspicion for cholecystitis. In addition to CAv, the following were reviewed by 3 radiologists: CBD diameter, cholelithiasis, impacted stone in the neck, sludge, gallbladder wall thickness > 3 mm, gallbladder transverse dimension ≥ 4 cm, longitudinal dimension ≥ 8 cm, tensile gallbladder fundus sign, pericholecystic fluid, pericholecystic echogenic fat, and sonographic Murphy sign.Of the 43 patients who underwent definitive treatment, 25 had acute cholecystitis (34%) and 18 (25%) had chronic cholecystitis. Average CAv measurements were 50 ± 16 cm/s (acute), 28 ± 8 cm/s (chronic), and 22 ± 8 cm/s (control; p < 0.0001). In univariate analysis, among patients who underwent definitive therapy, CAv ≥ 40 cm/s, gallbladder wall thickness, stone impaction, GB long dimension ≥ 8 cm, and elevated WBC were associated with acute cholecystitis (p < 0.05). In multivariate analysis, CAv ≥ 40 cm/s was the only statistically significant variable (p = 0.016). CAv ≥ 40 cm/s alone had a PPV of 94.7% and overall accuracy of 81.4% in diagnosing acute cholecystitis.CAv ≥ 40 cm/s is highly associated with acute cholecystitis in patients presenting to the ED with RUQ pain.

    View details for DOI 10.1007/s00261-021-03020-z

    View details for PubMedID 34216245

  • Effects of Contrast-Enhanced Ultrasound of Indeterminate Renal Masses on Patient Clinical Management: Retrospective Analysis from Two Institutions: Retrospective Analysis From 2 Institutions. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine Eisenbrey, J. R., Kamaya, A. n., Gummadi, S. n., Bird, K. n., Burrowes, D. n., Arias, D. n., Lallas, C. D., Trabulsi, E. J., Lyshchik, A. n. 2020


    To investigate the long-term impact of contrast-enhanced ultrasound (CEUS) on the treatment of patients with indeterminate renal masses.In this retrospective study, consecutive charts of all patients receiving renal CEUS at 1 of 2 academic medical centers between January 1, 2014, and December 31, 2018, were reviewed. Patients were included in the study if they had documented chronic renal disease (estimated glomerular filtration rate < 60 mL/min/1.73 m2 ) or prior nephrectomy and received CEUS for a previously untreated renal mass.A total of 215 lesions in 157 patients were used for analysis. Contrast-enhanced ultrasound provided a final treatment recommendation in 71.6% of lesions (154 of 215). Of these 154 lesions, 7.8% (12 of 154) were lost to follow-up despite CEUS suggesting malignancy; 15.6% (24 of 154) went directly for surgical intervention, with malignancy confirmed by pathologic results in 87.5% (21 of 24) of these cases; and the remaining 76.6% (118 of 154) were deemed benign and required no additional follow-up. Of the 118 lesions diagnosed by CEUS as benign and requiring no follow-up, none showed evidence of later renal cell carcinoma development and, only 5.1% (6 of 118) of the total population was referred for further cross-sectional imaging of the mass in question. In 28.4% of all lesions (61 of 215), CEUS resulted in a recommendation for surveillance imaging at a 6- to 12-month interval, and less than 10% (6 of 61) of these underwent additional cross-sectional imaging within the recommended 6 months after CEUS.These findings highlight the impact of CEUS on clinical treatment of indeterminate renal masses, including reducing the use of the potentially nephrotoxic contrast agents and providing a direct pathway to transplant.

    View details for DOI 10.1002/jum.15383

    View details for PubMedID 32657452